Drugs / HS-10541
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07615413 | Jun 2026 → Jun 2029 expected | cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10541 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07615413 ↗ |
| Route | Oral | “administered orally” NCT07615413 ↗ |